Challenges of anticoagulant therapy in atrial fibrillation—focus on gastrointestinal bleeding

A Scridon, AI Balan - International Journal of Molecular Sciences, 2023 - mdpi.com
The rising prevalence and the complexity of atrial fibrillation (AF) pose major clinical
challenges. Stroke prevention is accompanied by non-negligible risks, making anticoagulant …

Systematic review and meta-analysis of direct oral anticoagulants versus warfarin in atrial fibrillation with low stroke risk

KY Fong, YH Chan, C Yeo, GYH Lip, VH Tan - The American Journal of …, 2023 - Elsevier
Pivotal trials comparing direct oral anticoagulants (DOACs) against warfarin in patients with
atrial fibrillation (AF) predominantly involved patients with high stroke risk. This study aimed …

Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

AM Campos-Staffico, MP Dorsch, GD Barnes… - Frontiers in …, 2022 - frontiersin.org
Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has
focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) …

Direct oral anticoagulants as the first choice of anticoagulation for patients with peripheral artery disease to prevent adverse vascular events: a systematic review and …

E Pomozi, R Nagy, P Fehérvári, P Hegyi, B Kiss… - Journal of …, 2023 - mdpi.com
The best method of anticoagulation for patients with peripheral artery disease (PAD) is still a
topic of interest for physicians. We conducted a meta-analysis to compare the effects of …

Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions

A Gómez-Outes, ML Suárez-Gea… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Cardioembolic stroke, associated to nonvalvular atrial fibrillation (NVAF),
accounts for approximately one in every four strokes. Cardioembolic stroke has a bad …

Direct comparison of non-vitamin K antagonist oral anticoagulant versus warfarin for stroke prevention in non-valvular atrial fibrillation: a systematic review and meta …

Y Waranugraha, A Rizal, MFR Syaban… - The Egyptian Heart …, 2021 - Springer
Background To overcome the several drawbacks of warfarin, non-vitamin K antagonist oral
anticoagulants (NOACs) were developed. Even though randomized controlled trials (RCTs) …

Non‐synonymous alterations in AKR7A3 and ABCA6 correlate with bleeding in aged patients treated with rivaroxaban

M Zhao, Q Zhang, X Wang, Q Zhang… - Clinical and …, 2022 - Wiley Online Library
Rivaroxaban is an oral anticoagulant that inhibits thrombin and blocks coagulation cascade
through directly inactivating factors Xa. Despite rivaroxaban is widely used for prevention …

Challenges to Laboratory Monitoring of Direct Oral Anticoagulants

J Qiao, MH Tran - Clinical and Applied Thrombosis …, 2024 - journals.sagepub.com
Direct oral anticoagulants (DOACs) exert anticoagulation effect by directly inhibiting Factor
Xa (rivaroxaban, apixaban, and edoxaban) or thrombin (dabigatran). Though DOACs are …

Risk of intracranial hemorrhage between different direct oral anticoagulants in older patients seen in the emergency department with a head injury: A population …

K Grewal, CL Atzema, PC Austin, K de Wit… - Thrombosis …, 2022 - Elsevier
Introduction Patients taking direct oral anticoagulants (DOACs) are increasingly managed in
emergency departments (ED). It is unknown whether the risk of traumatic intracranial …

Mobile cardiac outpatient telemetry patch vs implantable loop recorder in cryptogenic stroke patients in the US–cost-minimization model

G Medic, N Kotsopoulos, MP Connolly… - Medical Devices …, 2021 - Taylor & Francis
Purpose The aim of this study was to compare costs and outcomes of mobile cardiac
outpatient telemetry (MCOT) patch followed by implantable loop recorder (ILR) compared to …